The Impact of Cost Sharing on Antidepressant Use Among Older Adults in British Columbia

National Institute of Mental Health, Bethesda, MD 20892-9629, USA.
Psychiatric Services (Impact Factor: 2.41). 05/2008; 59(4):377-83. DOI: 10.1176/
Source: PubMed


Antidepressant therapies are underused among older adults and could be further curtailed by patient cost-sharing requirements. The authors studied the effects of two sequential cost-sharing policies in a large, stable population of all British Columbia seniors: change from full prescription coverage to 10-25 dollars copayments (copay) in January 2002 and replacement with income-based deductibles and 25% coinsurance in May 2003.
PharmaNet data were used to calculate monthly dispensing of antidepressants (in imipramine-equivalent milligrams) among all British Columbia residents age 65 and older beginning January 1997 through December 2005. Monthly rates of starting and stopping antidepressants were calculated. Population-level patterns over time were plotted, and the effects of implementing cost-sharing policies on antidepressant use, initiation, and stopping were examined in segmented linear regression models.
Implementation of the copay policy was not associated with significant changes in level of antidepressant dispensing or the rate of dispensing growth. Subsequent implementation of the income-based deductible policy also did not lead to a significant change in dispensing level but led to a significant (p=.02) decrease in the rate of growth of antidepressant dispensing. The copay policy was associated with a significant (p=.01) drop in the frequency of antidepressant initiation among persons with depression. Income-based deductibles reduced the rate of increase in antidepressant initiation over time. Implementation of the copay and income-based deductible policies did not have significant effects on stopping rates.
Introducing new forms of medication cost sharing appears to have the potential to reduce some use and initiation of antidepressant therapy by seniors. The clinical consequences of such reduced use need to be clarified.

Full-text preview

Available from:
  • Source
    • "Grootendorst (2001) analysed the impact of referenced -based pricing on nitrates usage and cost reduction by using also the cost per milligram. Similar approach was found useful in case of comparison of the medicines prices for particular therapeutic groups (Wang 2008), which is also the case in our study. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background During the last three decades tremendous progress has been made in the discovery and development of a lot of new molecules in many pharmaceutical areas. These families of real innovative treatment comprise "originator" molecules (first molecule released, which can be under patent or with expired patent), as well a “generic” version of those originator molecules, whose patent has expired. Usually the patent expires 15–20 years after the creation of the originator molecule. Main objective This research focuses on the effects of the arrival of generic and or therapeutic competitors on the market, in terms of impact on the market share and prices. Methodology Between 2005 and 2007 we follow three classes of medicinal products in the cardiovascular area: ACE inhibitors, sartans and statins. They have been studied on the Bulgarian market because there is no regulation in the country stimulating the generic market. The official database of the Bulgarian Health Insurance Fund was used to test our two hypotheses concerning the impact of the generics on market share and prices. To test our hypotheses, a t-test analysis, Kolmogorov Smirnov, one and two way ANOVA analyses were performed. Results Our results confirm that the generic competition, in general, changes the market. These changes decrease the price of the medicines. The generic competition is not regulated in the country and this fact could negatively influence our study because it does not correspond to world trends. Furthermore, our results confirm that the creation of a sustainable generic pharmaceutical market requires active regulatory and marketing measures at all levels including incentives for manufactures, physicians and dispensers.
    Full-text · Article · Feb 2011 · Journal of Public Health
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although combination pharmacotherapy after myocardial infarction dramatically reduces morbidity and mortality, the full benefits of secondary prevention medications remain unrealized owing to medication non-adherence. Because financial barriers are a major determinant of non-adherence, we examined the costs and benefits of providing free medications to myocardial infarction patients who do not have private insurance and are ineligible for substantial public coverage. An economic evaluation combining decision analysis and Markov modelling was conducted to compare full public coverage of secondary prevention medications with the status quo. Costs and benefits were estimated using Canadian data wherever possible. The main outcome was the incremental cost-effectiveness ratio measured in cost per quality-adjusted life-year (QALY) gained. From the perspective of the publicly funded healthcare system, full coverage resulted in greater quality-adjusted survival than the status quo (7.02 vs. 6.13 QALYs) but at increased cost ($20,423 vs. $17,173). The incremental cost-effectiveness ratio (ICER) for full coverage compared to the status quo was $3,663/QALY. This result was robust to a wide range of sensitivity analyses. In a secondary analysis from the perspective of government, the ICER for full coverage compared to the status quo was $12,350/QALY. In this analysis, the ICER was sensitive to changes in price elasticity, but remained below $50,000/QALY as long as the elasticity remained below -0.035. Public payers in Canada should consider providing secondary prevention medications to myocardial infarction patients without private insurance free of charge. Full public coverage is cost-effective compared to the status quo.
    Preview · Article · Nov 2009 · Healthcare policy = Politiques de sante
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To examine the effect of Part D on 65-78-year-old noninstitutionalized dual eligibles' prescription utilization and expenditures. Random sample of unique pharmacy customers of a national retail pharmacy chain who filled at least one prescription during both 2005 and 2006. For each subject, we obtained claims data for every prescription filled between January 1, 2005, and April 31, 2007. Generalized estimating equations were used to examine the experience of a "treatment" group (dual eligibles between 65 and 78 years on January 1, 2005) with that of a "control" group (near-elderly patients with Medicaid coverage between 60 and 63 years on January 1, 2005) during the first 18 months after Part D implementation. Expenditures for the treatment and control groups tracked each other closely in the pre-Part D period. Immediately following the implementation of Part D, expenditures for both groups decreased and then leveled off. There were no significant changes in trends in the dual eligibles' out-of-pocket expenditures, total monthly expenditures, pill-days, or total number of prescriptions due to Part D. We find no evidence that Part D adversely affected pharmaceutical utilization or out-of-pocket expenditures of dual eligibles during the transition period, nor during the 16 months subsequent to Part D implementation.
    Full-text · Article · Dec 2009 · Health Services Research
Show more